The ACCELERATE Trial

Recommendations

Info

Index diagnosis Parameter Placebo (n=6054) Evacetrapib (n=6038) Acute coronary syndrome 31% 30% Mean months from event 5.7 5.5 Cerebrovascular atherosclerotic disease 12% 12% Peripheral arterial disease 14% 14% Diabetes with coronary artery disease 64% 65% Statin use 98% 97% Lipid levels Additional Baseline Characteristics High intensity statin use 46% 46% Mean LDL-cholesterol 81 mg/dL 82 mg/dL Mean HDL-cholesterol 45 mg/dL 45 mg/dL
Adherence and Retention Placebo (n=6054) Evacetrapib (n=6038) Completing end of study visit 98.7% 98.8% End of study visit not completed 1.3% 1.2% Study drug prematurely discontinued * 18.1% 16.4% Average months on study drug 25 25 Average months of study participation 29 29 *p
Page 1 and 2: The ACCELERATE Trial Impact of the
Page 3 and 4: Role of Cholesteryl Ester Transfer
Page 5 and 6: ACCELERATE Trial Design 12,092 pati
Page 7: Baseline Clinical Characteristics P
Page 11 and 12: Percent Change in LDL-C Levels Duri
Page 13 and 14: Secondary Efficacy Endpoints Placeb
Page 15 and 16: Systolic Blood Pressure During the
Page 17: ACCELERATE Data Sharing Initiative

The ACCELERATE Trial

Create successful ePaper yourself

Delete template?

Save as template?